Described here is a stepwise method of combining Fiber Optic RealShape technology and intravascular ultrasound to show the potential of merging both techniques, in view of the reduction of radiation exposure and improvement of navigation tasks and treatment success during an endovascular procedure for the treatment of peripheral arterial disease.
Vascular surgeons and interventional radiologists face chronic exposure to low-dose radiation during endovascular procedures, which may impact their health in the long term due to their stochastic effects. The presented case shows the feasibility and efficacy of combining Fiber Optic RealShape (FORS) technology and intravascular ultrasound (IVUS) to reduce operator exposure during the endovascular treatment of obstructive peripheral arterial disease (PAD).
FORS technology enables real-time, three-dimensional visualization of the full shape of guidewires and catheters, embedded with optical fibers that use laser light instead of fluoroscopy. Hereby, radiation exposure is reduced, and spatial perception is improved while navigating during endovascular procedures. IVUS has the capacity to optimally define vessel dimensions. Combining FORS and IVUS in a patient with iliac in-stent restenosis, as shown in this case report, enables passage of the stenosis and pre- and post-percutaneous transluminal angioplasty (PTA) plaque assessment (diameter improvement and morphology), with a minimum dose of radiation and zero contrast agent. The aim of this article is to describe the method of combining FORS and IVUS stepwise, to show the potential of merging both techniques in view of reducing radiation exposure and improving navigation tasks and treatment success during the endovascular procedure for the treatment of PAD.
Peripheral arterial disease (PAD) is a progressive disease caused by arterial narrowing (stenosis and/or occlusions) and results in reduced blood flow toward the lower extremities. The global prevalence of PAD in the population aged 25 and over was 5.6% in 2015, indicating that about 236 million adults live with PAD worldwide1,2. As the prevalence of PAD increases with age, the number of patients will only increase in the coming years3. In recent decades, there has been a major shift from open to endovascular treatment for PAD. Treatment strategies can include plain old balloon angioplasty (POBA), potentially combined with other techniques like a drug-coated balloon, stenting, endovascular atherectomy, and classic open atherectomy (hybrid revascularization) to improve vascularization toward the target vessel.
During endovascular treatment of PAD, image guidance and navigation are conventionally provided by two-dimensional (2D) fluoroscopy and digital subtraction angiography (DSA). Some major drawbacks of fluoroscopically guided endovascular interventions include the 2D conversion of 3D structures and movements, and the grayscale display of endovascular navigation tools, which is not distinctive from the grayscale display of the surrounding anatomy during fluoroscopy. Furthermore, and more importantly, the increasing number of endovascular procedures still results in high cumulative radiation exposure, which may impact the health of vascular surgeons and radiologists. This is despite the current radiation guidelines, which are based on the "as low as reasonably achievable" (ALARA) principle that aims to achieve the lowest radiation exposure possible when performing a procedure safely4,5. Moreover, to assess the results of endovascular revascularization (e.g., after POBA), generally, one or two 2D digital subtraction angiograms are made with nephrotoxic contrast to estimate the dynamic improvement of blood flow. With this, eyeballing is needed to assess the increase in blood flow. Further, this technique also has limitations regarding assessments of vessel lumen diameter, plaque morphology, and the presence of flow-limiting dissection after endovascular revascularisation. To overcome these problems, new imaging technologies have been developed to improve device navigation and hemodynamics after treatment, and to reduce radiation exposure and the use of contrast material.
In the presented case, we describe the feasibility and efficacy of combining Fiber Optic RealShape (FORS) technology and intravascular ultrasound (IVUS) to reduce operator exposure during the endovascular treatment of PAD. FORS technology enables real-time, 3Dvisualization of the full shape of specially designed guidewires and catheters by using laser light, which is reflected along optical fibers instead of fluoroscopy6,7,8. Hereby, radiation exposure is reduced, and the spatial perception of endovascular navigation tools is improved by using distinctive colors while navigating during endovascular procedures. IVUS has the capacity to optimally define vessel dimensions. The aim of this article is to describe the method of combining FORS and IVUS stepwise, to show the potential of merging both techniques in view of the reduction of radiation exposure, and the improvement of navigation tasks and treatment success during endovascular procedures for the treatment of PAD.
Case presentation
Here, we present a 65-year-old male with a history of hypertension, hypercholesterolemia, coronary artery disease, and infrarenal abdominal aortic and right common iliac artery aneurysms, treated with endovascular aneurysm repair (EVAR) in combination with a right sided iliac branched device (IBD). Years later, the patient developed acute lower extremity ischemia based on occlusion of the left iliac EVAR limb, requiring embolectomy of the left iliac EVAR limb and superficial femoral artery. In the same procedure, an aneurysm of the common iliac artery was eliminated by extension of the endograft into the external iliac artery.
Diagnosis, assessment, and plan
During the follow-up, a routine duplex ultrasound showed an increased peak systolic velocity (PSV) within the left iliac limb of the stent graft of 245 cm/s, in comparison to a PSV of 70 cm/s proximally. This correlated with a significant stenosis of >50% and a ratio of 3.5. A diagnosis of in-stent restenosis (ISR) of over 50% was subsequently confirmed by computed tomography angiography (CTA) imaging, with the additional suspicion that the stenosis was caused by thrombus. To prevent the recurrence of limb occlusion, a percutaneous transluminal angioplasty (PTA) was planned.
The University Medical Center Utrecht Medical Ethics Committee approved the study protocol (METC 18/422), and the patient provided informed consent for the procedure and protocol.
1. Patient screening
2. Vessel segmentation
3. Surgical preparation
4. Ultrasound-guided puncture of the left common femoral artery
5. Volume registration
6. FORS shape registration
NOTE: The FORS devices are registered inside the operation theatre to enable their usage without fluoroscopy.
7. Endovascular navigation
8. Pre-PTA IVUS diameter measurements
9. Transluminal percutaneous angiography (PTA) treatment
10. Post-PTA IVUS diameter measurements
11. Pressure measurements
The protocol used for the presented case shows the feasibility of combining the FORS technique and IVUS, with the aim to decrease radiation exposure and contrast usage in an endovascular procedure for PAD. The majority of the procedure is performed without X-ray, and zero contrast is used. Passage through the lesion is performed by using FORS (guidewire and catheter) technology. The steps in which the X-ray is used are described in the protocol; four fluoroscopic images (needed for volume and shape registration), changing of guidewires (0.035 standard and 0.014 workhorse), and during inflation of the PTA balloon (Table 1).
Instead of making a (contrast) 2D digital subtraction angiogram, the effect of POBA in this case is quantified by using IVUS. The lumen diameter increased from 4.8 mm pre-POBA to 7.0 mm post-POBA, and the cross-sectional lumen area increased from 27.7 mm2 to 43.8 mm2, respectively (Figure 1). After POBA, blood pressure measurements showed no significant drop distal to the area under consideration compared with the aortic area (blood pressure of 103/73 and 106/73 mmHg, respectively), confirming an adequate treatment.
The total fluoroscopic time was 1 min 53 s, with a total air kerma (AK) of 28.4 mGy and a dosis area product (DAP) of 7.87 Gy/cm2. Follow-up duplex ultrasound examination showed no residual stenotic lesion, and the patient indicated that walking distance improved. An overview of all IVUS measurements, blood pressure measurements, and total radiation exposure is presented in Table 2.
The combination of FORS and IVUS shows to be feasible in reducing radiation exposure and contrast usage, and enables an accurate treatment of a stenotic lesion and quantification of the result.
Presented protocol | Conventional therapy | |
Vessel volume segmentation | No radiation | Not applicable |
Volume registration | 2x Single shot exposures | Not applicable |
FORS shape registration | 2x Single shot exposures | Not Applicable |
Endovascular navigation | No radiation (FORS) | Fluoroscopy |
Changing guidewires | Fluoroscopy | Fluoroscopy |
Quantification of stenotic lesion | No radiation, no contrast (IVUS) | 2x DSA with contrast |
PTA treatment | Fluoroscopy | Fluoroscopy |
Quantification of treatment success | No radiation, no contrast (IVUS) | 2x DSA with contrast |
Pressure measurements | No radiation (FORS) | Fluoroscopy |
Table 1: Overview of the presented protocol and the use of radiation exposure, FORS, and IVUS during the procedure compared to conventional PTA treatment of a stenotic lesion. PTA = percutaneous transluminal angioplasty; FORS = Fiber Optic Realshape; IVUS = intravascular ultrasound; DSA = digital subtraction angiography.
IVUS Lumen diameter | ||
Pre-treatment | 4.0 mm | |
Post-treatment | 7.0 mm | |
IVUS Cross-sectional lumen area | ||
Pre-treatment | 27.7 mm2 | |
Post-treatment | 43.8 mm2 | |
Post-treatment pressure measurement | ||
Cranial to culprit area | 103/73 mmHg | |
Distal to culprit area | 106/73 mmHg | |
Radiation exposure parameters | ||
Fluoroscopy time | 00:01:53 (HH:MM:SS) | |
Air Kerma (AK) | 28.4 mGy | |
Dosis Area Product (DAP) | 7.87 Gy*cm2 |
Table 2: Overview of pre- and posttreatment IVUS-measured lumen diameter and cross-sectional lumen area, posttreatment pressure measurements, and radiation exposure outcomes. IVUS = intravascular ultrasound.
Figure 1: Pre and post treatment images. (A) Pretreatment assessment of the stenotic lesion and (B) post-treatment quantification of treatment success using IVUS. The minimal lumen diameter increases from 4.8 mm to 7.0 mm, and the cross-sectional lumen area from 27.7 mm2 to 43.8 mm2 after PTA treatment. Please click here to view a larger version of this figure.
To our knowledge, this case report is the first to discuss the combination of FORS and IVUS to limit radiation exposure and exclude the use of a contrast agent during endovascular intervention for PAD. The combination of both techniques during the treatment of this specific lesion seems to be safe and feasible. Furthermore, the combination of FORS and IVUS makes it possible to limit radiation exposure (AK = 28.4 mGy; DAP = 7.87 Gy*cm2) and eliminates the use of contrast agents during the procedure. The presented amount of radiation exposure and contrast volume are much lower compared to those from procedures in the same anatomical region reported in the literature; however, direct comparison of these results is difficult9,10,11. Radiation exposure and related parameters in peripheral endovascular interventions are significantly influenced by patient-related parameters (e.g., body mass index) and lesion characteristics (length, severity, and morphology). In general, however, the culprit lesion must be visualized for navigation purposes and to quantify the effect the endovascular treatment (in this case, POBA), which represents a relatively large proportion of the total procedural radiation exposure12. Since FORS is used in combination with a roadmap during navigation and IVUS for the assessment of treatment outcome, it is not necessary to obtain digital subtraction angiograms in this case. It is therefore very likely that significantly less radiation is used in this case than what would have been used in a conventional approach with fluoroscopic and DSA imaging.
A limitation of the presented case is that it concerns a relatively low complex lesion (short and non-calcified/TASC A), making this procedure a relatively straightforward intervention. However, Klaassen et al.13 showed that the use of a FORS guidewire and catheter is feasible for the recanalization of long and complex superficial femoral artery lesions (TASC D). The added value of combining FORS and IVUS has not been described yet.
Furthermore, the 2D volume registration of the roadmap is simplified in this case because of the pre-existing EVAR endograft. The aortic bifurcation and both iliac arteries are fairly fixed in terms of the anatomic position, so the differences between the segmented CTA and the actual anatomical position on the operating room (OR) table are relatively small. Arteries in the upper and especially lower leg, conversely, have much more freedom of movement. This increases the possibility of differences in anatomical orientation and rotation between the preoperative CTA and the actual position on the operating table, making it more challenging to precisely position the created roadmap via 2D volume registration. In these cases, positioning of the roadmap has to be adapted to the actual situation during the procedure.
Finally, volume and shape registration require additional and complicated tasks, and the current version of the FORS-enabled guidewire and catheter needs further development. The FORS guidewire is not back-loadable due to its tethered connection to the system. This makes it impossible to change a catheter over the wire once the guidewire is placed in the body, and many additional steps are currently required to switch from FORS to IVUS and vice versa. Addressing these issues in future versions of this guidewire will make it easier to use these technologies simultaneously.
In this case, we describe a successful treatment of a stenotic lesion in the proximal part of an iliac limb of an EVAR endograft, in which the combination of image fusion, FORS, and IVUS technology leads to minimal radiation exposure and no contrast medium use. In an era of increasing numbers of endovascular procedures and correlated increasing cumulative radiation exposure for both patients and treatment teams, the combination of these technologies shows a safe turn toward the possibility of minimizing or even eliminating radiation exposure and contrast usage during these procedures. In addition, the use of IVUS to quantify stenotic lesions and the direct treatment effect perioperatively provides a more objective outcome measure compared to the surgeons assessment of contrast flow during DSA. Future developments should aim at merging both techniques in one catheter, using the same interface and software as one solution. Furthermore, future research must include more patients with more complex lesions to demonstrate the effect on radiation exposure and contrast use, and to show whether merging of both techniques in one device has potential.
The authors have nothing to disclose.
AltaTrack Catheter Berenstein | Philips Medical Systems Nederland B.V., Best, Netherlands | ATC55080BRN | |
AltaTrack Docking top | Philips Medical Systems Nederland B.V., Best, Netherlands | ||
AltaTrack Guidewire | Philips Medical Systems Nederland B.V., Best, Netherlands | ATG35120A | |
AltaTrack Trolley | Philips Medical Systems Nederland B.V., Best, Netherlands | ||
Armada 8x40mm PTA balloon | Abbott laboratories, Illinois, United States | B2080-40 | |
Azurion X-ray system | Philips Medical Systems Nederland B.V, Best, Netherlands | ||
Core M2 vascular system | Philips Medical Systems Nederland B.V., Best, Netherlands | 400-0100.17 | |
Hi-Torque Command guidewire | Abbott laboratories, Illinois, United States | 2078175 | |
Perclose Proglide | Abbott laboratories, Illinois, United States | 12673-03 | |
Rosen 0.035 stainless steel guidewire | Cook Medical, Indiana, United States | THSCF-35-180-1.5-ROSEN | |
Visions PV .014P RX catheter | Philips Medical Systems Nederland B.V., Best, Netherlands | 014R |